Lotte Biologics is strengthening its position as a strategic partner by expanding its collaboration scope to include development stages. The company aims to establish a comprehensive partnership that spans from initial development to commercialization. This shift from mere production to development collaboration is expected to enhance the likelihood of future commercialization.
On May 18, Lotte Biologics announced that it has signed a contract with the UK-based biotech firm Otimo Pharma for the contract manufacturing of antibody drugs.
The company previously entered into a contract with Otimo Pharma in June of last year, and this new order marks an expansion of their partnership.
The latest agreement includes not only the production of active pharmaceutical ingredients (API) but also process development. Lotte Biologics will be responsible for producing the API for Otimo Pharma's antibody drug, 'Jankistomig,' at its Syracuse Bio Campus in New York.
Based at the Syracuse Bio Campus, Lotte Biologics provides CDMO services ranging from cell line development to large-scale contract manufacturing. Additionally, the company plans to establish a 'dual site' production system connecting North America and Asia through its first factory at the Songdo Bio Campus, which is set to be completed in August this year.
In March, Lotte Biologics was recognized as the 'Best New & Relaunch CDMO' at the prestigious 2026 CDMO Leadership Awards.
James Park, CEO of Lotte Biologics, stated, "We will actively support new drug development based on our CDMO capabilities that encompass process development to commercial production, and we aim to establish ourselves as a trusted partner in the global market."
* This article has been translated by AI.
Copyright ⓒ Aju Press All rights reserved.